{
    "clinical_study": {
        "@rank": "124500", 
        "arm_group": [
            {
                "arm_group_label": "chloroquine", 
                "arm_group_type": "Experimental", 
                "description": "150 mg chloroquine and lacebo , one tablet daily for 2 month"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Experimental", 
                "description": "150 mg chloroquine and lacebo , one tablet daily for 2 month"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy of Chloroquine comparing with placebo\n      for treatment of non- response HCV patients.. In this triple blind pilot study, 20 patients\n      with confirmed chronic hepatitis C will be randomize into treatment group (Chloroquine 150\n      mg daily, for 8  weeks) or control group (placebo once daily, for 8  weeks). Patients who\n      have receiving anti neoplastic, anti viral or Immunomedullator drugs during 6 months prior\n      to study, have co-infection Hepatitis A,C,D or HIV, severe liver or renal dysfunction, are\n      pregnant or breast fed, or refuse to sign informed consent will be excluded.. At the end of\n      therapy (12 weeks) and at baseline, first, second and third month after receiving drug and\n      placebo HCV Virus load, CBC LFT and biochemical parameters  will be evaluated and compared\n      between groups."
        }, 
        "brief_title": "\"Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study\"", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C Virus", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients who failed to achieve a decline of 2 log HCV RNA IU/ml after 12 weeks of\n             treatment\n\n          -  who never achieved undetectable HCV RNA during treatment of a minimum duration of 24\n             weeks\n\n        Exclusion Criteria:\n\n          -  Receiving anti neoplasm, anti viral or immunomedulator drugs during 6 months prior to\n             study\n\n          -  coinfection with Hepatitis A,C,D viruses or HIV\n\n          -  Severe dysfunction of liver and kidney\n\n          -  pregnancy\n\n          -  breast feeding\n\n          -  refusing to give informed consent\n\n          -  active Alcohol user\n\n          -  presence of decompensate cirrhosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02058173", 
            "org_study_id": "HP7-92", 
            "secondary_id": "HP7-92"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "chloroquine", 
                    "placebo"
                ], 
                "intervention_name": "150 mg/daily chloroquine compare to placebo for 12 week", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "chloroquine", 
                "intervention_name": "Chloroquine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chloroquine", 
                "Chloroquine diphosphate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 12, 2014", 
        "location": {
            "contact": {
                "email": "lankarani@mohme.gov.ir", 
                "last_name": "Kamran B Lankarani, M.D", 
                "phone": "098-711-2309615"
            }, 
            "facility": {
                "address": {
                    "city": "Shiraz", 
                    "country": "Iran, Islamic Republic of", 
                    "state": "Fars"
                }, 
                "name": "Health Policy Research Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "other_outcome": {
            "measure": "ALT response which is significant decrease in ALT-(biochemical response during Treatment)", 
            "safety_issue": "Yes", 
            "time_frame": "july 2014"
        }, 
        "overall_contact": {
            "email": "lankarani@mohme.gov.ir", 
            "last_name": "Kamran Bagheri Lankarani, M.D", 
            "phone": "098+-711-2309615"
        }, 
        "overall_official": {
            "affiliation": "Health policy research center", 
            "last_name": "Kamran B Lankarani, M.D", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Iran: Ethics Committee and Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Loss of HCV RNA at end of treatment which is 8 weeks", 
            "safety_issue": "Yes", 
            "time_frame": "march 2014"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02058173"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shiraz University of Medical Sciences", 
            "investigator_full_name": "Payam Peymani", 
            "investigator_title": "PhD Student of pharmacoepidemiology,health policy reseach center,Shiraz University of Medical Sciences", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Two log decrease in HCV RNA at the end of treatment", 
            "safety_issue": "Yes", 
            "time_frame": "july 2014"
        }, 
        "source": "Shiraz University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shiraz University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}